- Medix Biochemica收購(gòu)了美國(guó)EastCoast Bio (“ECB”)業(yè)務(wù)；ECB為全球IVD生產(chǎn)商提供高質(zhì)量的抗原、抗體以及阻斷劑
Medix Biochemica has acquired the business of US-based EastCoast Bio (“ECB”), a provider of high-quality antigens, antibodies and blocking buffers for the in vitro Diagnostics (IVD) manufacturing industry worldwide
- 通過(guò)此次并購(gòu)，全球IVD客戶(hù)將得以通過(guò)整合后的銷(xiāo)售網(wǎng)絡(luò)更輕松地獲得所有相關(guān)產(chǎn)品
As a result of the acquisition, the complementary bioreagent portfolios of Medix Biochemica and ECB will be available to the global IVD customer base from a comprehensive global sales network
- 本次并購(gòu)與Medix Biochemica通過(guò)整合IVD供應(yīng)鏈、成為IVD行業(yè)關(guān)鍵原料首選供應(yīng)商的戰(zhàn)略完全一致
The acquisition is in line with Medix Biochemica’s strategy to consolidate the IVD supply chain and become the #1 supplier of critical raw materials to the IVD industry
- ECB的創(chuàng)始人及CFO Clark L McDermith和總裁Pamela F Williams將在隨后的整合中繼續(xù)在Medix Biochemica 免疫診斷原料業(yè)務(wù)部擔(dān)任重要職務(wù)
ECB’s founder and CFO Clark L McDermith and President Pamela F Williams will continue in key roles with Medix Biochemica’s Immunodiagnostic Reagents Business Unit following the transaction
Medix Biochemica收購(gòu)了美國(guó)EastCoast Bio (“ECB”)業(yè)務(wù)；ECB為全球IVD生產(chǎn)商提供高質(zhì)量的抗原、抗體以及阻斷劑。本次并購(gòu)擴(kuò)充了Medix Biochemica在數(shù)個(gè)診斷領(lǐng)域的抗體抗原產(chǎn)品線，諸如藥物濫用、傳染病、動(dòng)物檢測(cè)等。 ECB團(tuán)隊(duì)的加入也將加強(qiáng)Medix Biochemica在北美的商務(wù)能力，與此同時(shí)，ECB業(yè)務(wù)也將得益于Medix Biochemica在歐洲和中國(guó)強(qiáng)大的本地團(tuán)隊(duì)。
Medix Biochemica has acquired the business of EastCoast Bio, a provider of high-quality antigens, antibodies and blocking buffers for the In-Vitro Diagnostic (IVD) manufacturing industry worldwide. The acquisition broadens Medix Biochemica’s antibody and antigen offering in several diagnostic areas, including Drugs of Abuse, Infectious Disease and Veterinary testing. Furthermore, the addition of the ECB team further strengthens the commercial presence of Medix Biochemica in North America, while ECB will benefit from Medix Biochemica’s strong local commercial presence in Europe and China.
并購(gòu)?fù)瓿珊螅珽CB團(tuán)隊(duì)及運(yùn)營(yíng)將并入Medix Biochemica免疫診斷原料部。ECB創(chuàng)始人兼CFO Clark L McDermith以及總裁Pamela F Williams將繼續(xù)在Medix Biochemica 免疫診斷原料業(yè)務(wù)部擔(dān)任重要職務(wù)。
As a result of the transaction, the organization and operations of ECB will be merged with Medix Biochemica’s Immunodiagnostic Reagents Business Unit. ECB’s founder and CFO Clark L McDermith and President Pamela F Williams will continue with Medix Biochemica’s Immunodiagnostic Reagents Business Unit in key roles.
ECB由Clark L McDermith創(chuàng)立于1995年，是全球性IVD行業(yè)供應(yīng)商，主要提供高質(zhì)量的抗原、抗體、阻斷劑以及定制的免疫試劑。ECB尤其以其領(lǐng)先的藥物濫用、傳染病、以及動(dòng)物檢測(cè)相關(guān)抗體、抗原、以及魚(yú)來(lái)源的阻斷劑而知名。ECB總部位于美國(guó)緬因州North Berwick市。
Founded in 1995 by Clark L McDermith, ECB is a supplier of high-quality antigens, antibodies, blocking buffers, and specialized immunoassay reagents for the IVD manufacturing industry worldwide. The company is particularly well known for its leading portfolio of Drugs of Abuse, Infectious Disease and Veterinary antibodies and antigens as well as for its Fish Blocking products. ECB is headquartered in North Berwick, Maine.
“與Clark及Pam領(lǐng)導(dǎo)下的ECB建立伙伴關(guān)系令人興奮，他們已經(jīng)推出了很廣的產(chǎn)品線、建立了高素質(zhì)的團(tuán)隊(duì)，并有極好的財(cái)務(wù)表現(xiàn)。本次并購(gòu)體現(xiàn)了Medix Biochemica的戰(zhàn)略，即進(jìn)行IVD行業(yè)供應(yīng)鏈整合、讓我們客戶(hù)的供應(yīng)鏈更強(qiáng)大。我們的長(zhǎng)期目標(biāo)是成為IVD試劑生產(chǎn)商的首選關(guān)鍵原料供應(yīng)商。這一動(dòng)作將大大擴(kuò)充我們的高品質(zhì)IVD原料產(chǎn)品線，提高我們?cè)谒幬餅E用及傳染病檢測(cè)領(lǐng)域的原料供應(yīng)能力。而且，ECB的加入、結(jié)合前不久對(duì)同為美國(guó)公司的Lee Biosolutions的收購(gòu)，還將進(jìn)一步強(qiáng)化我們?cè)诿绹?guó)這一戰(zhàn)略性市場(chǎng)的本地服務(wù)能力”，Medix Biochemica首席執(zhí)行官Steve Ferguson如此說(shuō)。
“We are excited about entering into this partnership with ECB which, under the leadership of Clark and Pam, has developed a broad product portfolio, built a highly competent team and achieved excellent financial results. The acquisition demonstrates Medix Biochemica’s strategy to consolidate the IVD supply chain and enhance supply chain visibility for our customers. Our long-term aim is to become the #1 supplier of critical raw materials for IVD test manufacturers. This move broadens our high-quality product portfolio of IVD raw materials and expands our capability into Drugs of Abuse and Infectious Disease testing. On top of this, ECB further strengthens our local presence in the strategically important U.S. market, building on our recent acquisition of Lee Biosolutions in the country”, says Steve Ferguson, CEO of Medix Biochemica.
“ECB業(yè)務(wù)連年持續(xù)增長(zhǎng)，Medix Biochemica是IVD行業(yè)公認(rèn)的單克隆抗體原料的領(lǐng)先供應(yīng)商，產(chǎn)能驚人，在歐洲和中國(guó)都有出眾的商務(wù)網(wǎng)絡(luò)，與Medix Biochemica合并對(duì)我們的業(yè)務(wù)是件大好事，對(duì)我們的同事來(lái)說(shuō)也很棒，對(duì)我們的客戶(hù)來(lái)說(shuō)更是天作之合”，ECB的創(chuàng)始人兼首席財(cái)務(wù)官 Clark L McDermith說(shuō)。
“ ECB has consistently grown year on year and coming together with Medix Biochemica who are recognized as pioneers in monoclonal antibodies with significant product capability and distribution in Europe and China, is good for our business, good for our staff and above all, great for our customers”, says Clark L McDermith, founder and CFO of ECB.
如需更多信息，請(qǐng)聯(lián)系：
For more information:
Medix Biochemica中國(guó)商務(wù)團(tuán)隊(duì)
Commercial Team of Medix Biochemica China
Tel +86 21 6811 9180, 6811 9181, 6811 9105
Email: medixchina@medixbiochemica.com
Pamela F Williams, ECB總裁
Pamela F Williams, President of ECB
Tel +1 207 676 7639
Email: pamelaw@eastcoastbio.com